Gene therapy for laryngeal paralysis

Akihiro Shiotani, Koichiro Saito, Koji Araki, Kazuhisa Moro, Kazuhiko Watabe

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: The surgical options for laryngeal paralysis only achieve static changes of vocal fold position. Laryngeal reinnervation procedures have had little impact on the return of dynamic laryngeal function. The development of a new treatment for laryngeal paralysis, aimed at the return of dynamic function and neurologic restoration and regeneration, is necessary. Methods: To assess the possibility of gene therapy for laryngeal paralysis aiming for the return of dynamic laryngeal function, we investigated the therapeutic effects of gene therapy using rat laryngeal paralysis models. Results: In a rat vagal nerve avulsion model, we transferred glial cell line-derived neurotrophic factor (GDNF) gene into the nucleus ambiguus using an adenovirus vector. Two and 4 weeks after the GDNF gene transfer, a significantly larger number of surviving motoneurons was observed. These neuroprotective effects of GDNF gene transfer were enhanced by simultaneous brain-derived neurotrophic factor gene transfer. In a rat recurrent laryngeal nerve crush model, we transferred GDNF gene into recurrent laryngeal nerve fibers after crush injury. Two and 4 weeks after GDNF gene transfer, we observed significantly faster nerve conduction velocity and better vocal fold motion recovery. Conclusions: These results indicate that gene therapy could be a future treatment strategy for laryngeal paralysis. Further studies will be necessary to demonstrate the safety of the vector before clinical application.

Original languageEnglish
Pages (from-to)115-122
Number of pages8
JournalAnnals of Otology, Rhinology and Laryngology
Volume116
Issue number2
Publication statusPublished - 2007 Feb

Fingerprint

Vocal Cord Paralysis
Glial Cell Line-Derived Neurotrophic Factor
Genetic Therapy
Genes
Recurrent Laryngeal Nerve
Vocal Cords
Nerve Crush
Medulla Oblongata
Neural Conduction
Brain-Derived Neurotrophic Factor
Motor Neurons
Neuroprotective Agents
Therapeutic Uses
Nerve Fibers
Adenoviridae
Nervous System
Regeneration
Safety
Therapeutics

Keywords

  • BDNF
  • Brain-derived neurotrophic factor
  • Functional recovery
  • GDNF
  • Gene therapy
  • Glial cell line-derived neurotrophic factor
  • Motoneuron loss
  • Nerve conduction velocity

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Shiotani, A., Saito, K., Araki, K., Moro, K., & Watabe, K. (2007). Gene therapy for laryngeal paralysis. Annals of Otology, Rhinology and Laryngology, 116(2), 115-122.

Gene therapy for laryngeal paralysis. / Shiotani, Akihiro; Saito, Koichiro; Araki, Koji; Moro, Kazuhisa; Watabe, Kazuhiko.

In: Annals of Otology, Rhinology and Laryngology, Vol. 116, No. 2, 02.2007, p. 115-122.

Research output: Contribution to journalArticle

Shiotani, A, Saito, K, Araki, K, Moro, K & Watabe, K 2007, 'Gene therapy for laryngeal paralysis', Annals of Otology, Rhinology and Laryngology, vol. 116, no. 2, pp. 115-122.
Shiotani A, Saito K, Araki K, Moro K, Watabe K. Gene therapy for laryngeal paralysis. Annals of Otology, Rhinology and Laryngology. 2007 Feb;116(2):115-122.
Shiotani, Akihiro ; Saito, Koichiro ; Araki, Koji ; Moro, Kazuhisa ; Watabe, Kazuhiko. / Gene therapy for laryngeal paralysis. In: Annals of Otology, Rhinology and Laryngology. 2007 ; Vol. 116, No. 2. pp. 115-122.
@article{b3f05ab4cc744ee78ce46e45533e232a,
title = "Gene therapy for laryngeal paralysis",
abstract = "Objectives: The surgical options for laryngeal paralysis only achieve static changes of vocal fold position. Laryngeal reinnervation procedures have had little impact on the return of dynamic laryngeal function. The development of a new treatment for laryngeal paralysis, aimed at the return of dynamic function and neurologic restoration and regeneration, is necessary. Methods: To assess the possibility of gene therapy for laryngeal paralysis aiming for the return of dynamic laryngeal function, we investigated the therapeutic effects of gene therapy using rat laryngeal paralysis models. Results: In a rat vagal nerve avulsion model, we transferred glial cell line-derived neurotrophic factor (GDNF) gene into the nucleus ambiguus using an adenovirus vector. Two and 4 weeks after the GDNF gene transfer, a significantly larger number of surviving motoneurons was observed. These neuroprotective effects of GDNF gene transfer were enhanced by simultaneous brain-derived neurotrophic factor gene transfer. In a rat recurrent laryngeal nerve crush model, we transferred GDNF gene into recurrent laryngeal nerve fibers after crush injury. Two and 4 weeks after GDNF gene transfer, we observed significantly faster nerve conduction velocity and better vocal fold motion recovery. Conclusions: These results indicate that gene therapy could be a future treatment strategy for laryngeal paralysis. Further studies will be necessary to demonstrate the safety of the vector before clinical application.",
keywords = "BDNF, Brain-derived neurotrophic factor, Functional recovery, GDNF, Gene therapy, Glial cell line-derived neurotrophic factor, Motoneuron loss, Nerve conduction velocity",
author = "Akihiro Shiotani and Koichiro Saito and Koji Araki and Kazuhisa Moro and Kazuhiko Watabe",
year = "2007",
month = "2",
language = "English",
volume = "116",
pages = "115--122",
journal = "Annals of Otology, Rhinology and Laryngology",
issn = "0003-4894",
publisher = "Annals Publishing Company",
number = "2",

}

TY - JOUR

T1 - Gene therapy for laryngeal paralysis

AU - Shiotani, Akihiro

AU - Saito, Koichiro

AU - Araki, Koji

AU - Moro, Kazuhisa

AU - Watabe, Kazuhiko

PY - 2007/2

Y1 - 2007/2

N2 - Objectives: The surgical options for laryngeal paralysis only achieve static changes of vocal fold position. Laryngeal reinnervation procedures have had little impact on the return of dynamic laryngeal function. The development of a new treatment for laryngeal paralysis, aimed at the return of dynamic function and neurologic restoration and regeneration, is necessary. Methods: To assess the possibility of gene therapy for laryngeal paralysis aiming for the return of dynamic laryngeal function, we investigated the therapeutic effects of gene therapy using rat laryngeal paralysis models. Results: In a rat vagal nerve avulsion model, we transferred glial cell line-derived neurotrophic factor (GDNF) gene into the nucleus ambiguus using an adenovirus vector. Two and 4 weeks after the GDNF gene transfer, a significantly larger number of surviving motoneurons was observed. These neuroprotective effects of GDNF gene transfer were enhanced by simultaneous brain-derived neurotrophic factor gene transfer. In a rat recurrent laryngeal nerve crush model, we transferred GDNF gene into recurrent laryngeal nerve fibers after crush injury. Two and 4 weeks after GDNF gene transfer, we observed significantly faster nerve conduction velocity and better vocal fold motion recovery. Conclusions: These results indicate that gene therapy could be a future treatment strategy for laryngeal paralysis. Further studies will be necessary to demonstrate the safety of the vector before clinical application.

AB - Objectives: The surgical options for laryngeal paralysis only achieve static changes of vocal fold position. Laryngeal reinnervation procedures have had little impact on the return of dynamic laryngeal function. The development of a new treatment for laryngeal paralysis, aimed at the return of dynamic function and neurologic restoration and regeneration, is necessary. Methods: To assess the possibility of gene therapy for laryngeal paralysis aiming for the return of dynamic laryngeal function, we investigated the therapeutic effects of gene therapy using rat laryngeal paralysis models. Results: In a rat vagal nerve avulsion model, we transferred glial cell line-derived neurotrophic factor (GDNF) gene into the nucleus ambiguus using an adenovirus vector. Two and 4 weeks after the GDNF gene transfer, a significantly larger number of surviving motoneurons was observed. These neuroprotective effects of GDNF gene transfer were enhanced by simultaneous brain-derived neurotrophic factor gene transfer. In a rat recurrent laryngeal nerve crush model, we transferred GDNF gene into recurrent laryngeal nerve fibers after crush injury. Two and 4 weeks after GDNF gene transfer, we observed significantly faster nerve conduction velocity and better vocal fold motion recovery. Conclusions: These results indicate that gene therapy could be a future treatment strategy for laryngeal paralysis. Further studies will be necessary to demonstrate the safety of the vector before clinical application.

KW - BDNF

KW - Brain-derived neurotrophic factor

KW - Functional recovery

KW - GDNF

KW - Gene therapy

KW - Glial cell line-derived neurotrophic factor

KW - Motoneuron loss

KW - Nerve conduction velocity

UR - http://www.scopus.com/inward/record.url?scp=33847316167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847316167&partnerID=8YFLogxK

M3 - Article

VL - 116

SP - 115

EP - 122

JO - Annals of Otology, Rhinology and Laryngology

JF - Annals of Otology, Rhinology and Laryngology

SN - 0003-4894

IS - 2

ER -